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Background: HPV screening has been shown to be more cost-effective than cytology screening under most
scenarios. Furthermore, it should be offered only in organized programmes with good quality assurance
mechanisms. This study analyses the comparative cost of the current policy of opportunistic cytology screening
vs. a hypothetical organized programme based on primary HPV screening. Methods: Total cervical cancer expend-
iture was defined as the sum of three cost elements: (i) direct (medical and non-medical) costs, obtained from a
calibrated Markov model of the natural history of HPV and cervical cancer; (ii) programmatic costs, estimated
based on other organized screening programmes; and (iii) indirect costs, extrapolated from previously published
data. Results: Organized HPV screening at 5-year intervals costs consistently less across all coverage levels than
opportunistic cytology screening at 3-year intervals. The current annual direct medical cost to the public health
system of the opportunistic cytology at 40% coverage is estimated at E33.2 per woman screened aged 25–64.
Under an organized programme of primary HPV screening at 70% coverage, the cost is estimated to be E18.4 per
woman screened aged 25–64. Conclusion: Our study concludes that the economic resources currently devoted to
providing opportunistic cytology screening to 40% of the target population at 3-year intervals could be more
effectively used to screen 70% of the target population at 5-year intervals by switching to an organized
programme based on primary HPV screening. This finding is of relevance to other European countries or
regions with similar screening policies and health infrastructures.
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Introduction
As a part of a comprehensive economic assessment, it is essentialto know in advance the total health expenditure of implement-
ing a new intervention that has already shown to be cost-effective.1
This costing approach is increasingly required by public health
decision-makers, along with cost-effectiveness analysis, because
predicts the potential impact on the health care system and can be
useful for resource or budget planning.2 Thus, policy-makers could
better inform the prioritization of health interventions by knowing
the financial resources required to implement each of the available
alternatives.3
Organized cytology screening programmes are well-established as
an effective and efficient means of preventing cervical cancer,
whether used alone or, preferably, in combination with the pre-
teen human papillomavirus (HPV) vaccine.4 For its part, opportun-
istic screening tends to be marked by overscreening of an extensive
low-risk population, combined with virtually non-existent screening
among higher risk groups.5 Both organized and opportunistic
screening lead to declines in cervical cancer incidence and
mortality, though drops are substantially lower and come at a
higher cost when following an opportunistic system.4,6
In Europe, several countries have national organized programmes
to screen for cervical cancer,7 though others, like Germany, Austria,
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Spain and Belgium, have stuck to opportunistic or partially
organized screening programmes.8 Meanwhile, primary HPV DNA
testing has emerged as a more effective means of prevention than
traditional cytology. It also offers longer-term protection in women
over the age of 30, thereby lengthening the screening interval for
HPV negative women and improving cost-effectiveness of HPV
testing vs. cytology screening.9 However, despite an increasing
body of evidence in favour of primary HPV screening, most
European countries tend only to use HPV testing as triage for cyto-
logical abnormalities.8 Successful HPV screening carries the caveat
that it must be implemented as part of an organized programme
with high coverage and good quality assurance mechanisms.10
Therefore, given suitable infrastructure, such programmes would
allow the same resources to be used more efficiently, covering a
larger group of women in countries with some spontaneous or
organized activity.11
In Spain, the national health system provides universal public
health care independently administered by the 17 Autonomous
Regions. In the Autonomous Region of Catalonia, cervical cancer
screening is opportunistic, unlike population-based breast and
colorectal cancer screening that have been organized since 1992
and 2000, respectively.12 Current guidelines recommend that
women aged 25–65 receive a cytology test every 3 years with HPV
testing for triage in some specific cases.13 It is estimated that the
Catalan public health system covers around 40% of the target group,
while private providers reach a further 30%.14 The Catalan
Department of Health has set up a working committee to develop
a new protocol for the incorporation of HPV screening as the
primary screening method. Further, in Catalonia, a school-based
HPV vaccination programme for girls aged 11–12 years was
brought into the immunization schedule in 2008. In 2015–2016
achieved 82.8% coverage for the full three-dose course.15
As in many European countries, budget constraints have
characterized the public health sector in Spain in recent years.
Therefore, being able to calculate the costs of all the available
prevention strategies is key to assure that health resources are used
as efficiently as possible. This study aims to present an analysis of the
economic evidence for switching to a hypothetical organized
programme based on primary HPV screening, compared to the
current policy of opportunistic cervical screening by cytology test
by means of a calibrated simulation model to Catalonia.
Methods
The target population figures were extracted from data compiled by
the Government of Catalonia indicating that 979 177 women aged
25–64 were attended at primary health centres, of a total 3 255 325
women aged 10–84 based on a 2015 postcensal estimate.16
Type of costs
Total cervical cancer expenditure is defined as the sum of three cost
elements for both screening strategies: direct (medical and non-
medical), programmatic and indirect costs. Direct medical costs
are those associated with the screening of asymptomatic women in
the target group, including prevention, diagnosis and follow-up of
cervical abnormalities, and the treatment of cancers and precancer-
ous lesions. Direct non-medical costs are related to patient
transport. In this study, they have been obtained using a
simulation model of the natural history of HPV and cervical
cancer, described below.17 Programmatic costs are those of imple-
menting an organized programme, from preparing and sending
invitation letters, information brochures, results letters, reminder
calls, to the need for additional administrative staff. They have
been estimated based on other such screening programmes in
Catalonia.18 Indirect costs include the productivity loss of the
patient associated to morbidity and to premature mortality. Our
data have been extrapolated from Oliva et al.,19 using the human-
capital approach, which takes the patient’s perspective.20 A societal
perspective was adopted, with unit costs indexed to 2017
(Supplementary appendix).
Screening strategies
This work analyzed two screening strategies: the current protocol
based on opportunistic cytology screening at 3-year intervals for
women aged 25–65,13 and a hypothetical organized programme
based on primary HPV testing at 5-year intervals for women aged
35–64 with cytology triage for HPV-positive women and cytology
for women aged 25–34.11 This last strategy showed to be cost-
effective in a previous analysis.17
Opportunistic screening at 3-year intervals was based on the fact
that, of the women who get themselves checked, 15% schedule
repeat visits every year, 15% every 2 years, 50% every 3 years, 15%
every 4 years and 5% every 5 years.14 For the organized screening
programme, regular 5-year intervals were assumed for all visits.
Coverage was estimated based on adherences of 40%, 70% and
100%.
Structure and calibration of the simulation model
The simulation model used in this study was adapted from a
previously validated model of HPV and cervical cancer.17 Briefly, a
discrete-time, stochastic Markov chain model that simulates the
natural history of HPV infection and cervical cancer was
calibrated to the best epidemiological data available from
Catalonia—i.e. age-specific HPV prevalence and cervical cancer
incidence. This closed model consists of 12 mutually exclusive
health states where the transition probabilities vary by age. It
follows a single cohort of 10-year-old girls using 1-year increments
until they reach the age of 84, or die. Starting from a matrix
calibrated to Spanish data, each model parameter was varied itera-
tively by the Nelder-Mead search algorithm, which is very efficient
and has been recommended in the literature as a suitable option to
conduct a calibration process in this context.21,22 This model allows
recording outcomes such as the number of procedures, precancerous
lesions, detected cancers and deaths, life expectancy and lifetime
costs associated with each strategy. Further information on the epi-
demiological data used and calibration are provided in the
Supplementary appendix.
Analysis
For both screening strategies, total annual costs and annual costs per
woman (>9 years old) and per screened woman aged 25–64 were
compared. Since the first vaccinated pre-teen girls in Catalonia will
not reach screening age until 2022, vaccination was not considered
in the base-case scenario. The unit costs for screening and vaccin-
ation were estimated from a societal perspective using multiple
sources (Supplementary appendix).15,23 Specifically, this study
considered a total cost per cytology of E74.50 and per HPV test
of E81.60, figures which include all consumables, equipment,
facilities, staff, laboratory transport and patient time costs.
Two one-way sensitivity analysis were performed, one assuming
the same unit cost for both cytology and HPV screening, and
another assuming the HPV 16/18 vaccination of pre-teen girls at
aged 12 with 82.8% coverage.15 The HPV vaccine tender price is
E102.90 for the full three doses.
Lifetime costs are presented both undiscounted, to simulate
current values, and discounted at an annual rate of 3% to
simulate the reduction of future costs.
Results
A comparison of model predictions with the latest observed data for
opportunistic cytology screening in Catalonia at 3-year intervals and
Moving towards an organized cervical cancer screening 1133
40% coverage is performed in table S3 of the Supplementary
appendix.14,23
Impact assessment on the Catalan health budget
For the current opportunistic cytology screening at 3-year intervals
and 40% coverage, total direct costs are estimated at E28.0 M
annually (E23.0 M medical and E5.0 non-medical; E9.9 M
discounted) (table 1), representing 74% of total cervical cancer ex-
penditure. Comparatively, the total direct cost of an organized
programme based on primary HPV screening at 5-year intervals
and the same coverage is estimated at around E18.7 M (E16.0 M
medical and E2.6 non-medical; E6.5 M discounted), representing
63% of total expenditure. In both cases direct medical costs
account for over 80% of total direct costs.
Current total cervical cancer expenditure stands at E37.7 M
(E13.3 M discounted), compared to the E29.6 M (E10.3 M
discounted) it would cost to implement the organized programme.
These figures include the costs of productivity loss, estimated at over
E9.7 M in both cases and accounting for 26% of current total ex-
penditure and 33% of total expenditure under the proposed
programme. In the case of the latter, it also includes the program-
matic cost, which accounts for just 3.9% of total expenditure. Thus,
at 40% coverage, total expenditure decreases by 21.5% when moving
from the current opportunistic cytology screening to an organized
primary HPV screening. This drop is mainly attributable to the
33.5% decrease in direct costs, given that costs of productivity loss
remain stable and programmatic costs are only incurred in the latter
instance.
The effect of raising coverage on the costs is shown in figure 1.
For instance, when coverage is raised to 70%, total expenditure
under the current system increases to E51.3 M (E18.8 M
discounted). Under an organized programme based on HPV
screening, 70% coverages gives a total expenditure of E37.7 M
(E13.6 M discounted), rising to E44.8 M (E16.9 M discounted) at
100% coverage. Organized HPV screening at 5-year intervals is
therefore consistently less expensive across than opportunistic
cytology screening at 3-year intervals. Indeed, current expenditure
in Catalonia would cover 71.4% of women of target age if spent on
organized HPV screening.
The current annual direct medical cost to the Catalan public
health system per woman is estimated at E7.1, increasing to E33.2
if only women of target age screened are taken into account
(figure 2). Under an organized programme, even if coverage is
rasen to 70%, the annual direct medical cost per woman screened
is estimated at E6.9, increasing to just E18.4 per woman of target
age screened.
Table 2 summarises the results of the sensitivity analysis. Direct
costs are found to be largely insensitive to the addition of the pre-
teen HPV vaccination at 82.8% coverage, and much the same
between the equal cost of HPV screening and traditional cytology.
The complete results for all cost categories, at different coverage
rates, for discounted and undiscounted total costs, per woman
(> 9 years old) and per woman aged 25–64 screened are available
in the Supplementary appendix.
Discussion
According to the EU Advisory Committee on Cancer Prevention,
cancer screening in Europe should be offered only in organized
programmes with quality assurance at all levels.24 Evidence shows
that participation and equity of access could be improved with this
approach.25 Additionally, several modelling studies, including a
model calibrated to Spain, have shown that HPV screening is
more cost-effective than cytology screening under most
scenarios.9,17 Our study concludes that, by switching to an
organized programme of primary HPV screening at 5-year
intervals, the same economic resources as currently used to screen
40% of women in the target age group in Catalonia could be used
more efficiently to provide slightly over 70% coverage. This
conclusion would be even more favourable had we factored the
pre-teen HPV vaccination into the base-case scenario, given the
fewer infections and the higher sensitivity of the HPV test.
Further, in HPV-vaccinated populations, the initial screening age
should be raised and the screening intervals extended,17 resulting
in even lower overall expenditure.
The current opportunistic protocol in Catalonia covers 40% of
women by conventional cytology screening every 3 years. This work
shows that the total direct cost to the public health system for
cytology screening is E28.0 M, including screening, follow-up and
treatment. This corresponds to around E8.6 per woman and E40.4
per woman aged 25–64 screened. This study estimates that switching
to an organized programme of primary HPV screening at 5-year
intervals and the same 40% coverage would leave total direct costs
at 18.7 M. This amounts to E5.7 per woman and E26.9 per woman
aged 25–64 screened. This cost would increase to E26.8 M if
coverage were raised to 70%, corresponding to E8.2 per women
and E22.1 per woman aged 25–64 screened. Increasing coverage
to 70% under the current protocol would generate a huge burden
on public finances, causing direct medical costs to increase by >60%.
Meanwhile, the same resources spent under the current protocol at
40% coverage would cover 71% of the target female population in
Catalonia under an organized programme of HPV screening. A
policy that scaled up coverage to a hypothetical 100% would
increase the cost of HPV screening by just 5–10%, depending on
what cost categories were included. Direct costs account for the bulk
of total expenditure in both strategies, though more so under the
current opportunistic protocol (74% vs. 55%). Switching to an
organized programme based on HPV screening at 40% coverage
would bring annual savings in direct costs of 9.3 ME. Costs of prod-
uctivity loss remain largely stable across both strategies, decreasing
progressively as coverage increases from 40% to 100% (from 29% to
Table 1 Estimated annual cost (direct, programmatic and indirect) of current opportunistic cytology screening vs. an organized programme
based on primary HPV screening, both at 40% coverage (E2017)
Cost category Opportunistic screening with 3y-cytology Organized screening with 5y-HPV testing
(40% coverage) (40% coverage)
Undiscounted Discounted Undiscounted Discounted
Total direct cost E28 050 016 E9 911 396 E18 666 460 E6 478 753
Direct medical cost E23 044 544 E8 017 296 E16 038 665 E5 443 275
Direct non-medical cost E5 005 471 E1 894 100 E2 627 795 E1 035 478
Programmatic cost – – E1 140 566 E388 106
Indirect cost E9 679 273 E3 420 144 E9 807 769 E3 404 079
Total cost E37 729 288 E13 331 540 E29 614 795 E10 270 938
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13% of total expenditure for HPV screening). This is because costs
of productivity loss correlate to morbidity and mortality: the higher
the coverage, the lower the number of incident cases and deaths
resulting from cervical cancer. For programmatic costs, the
opposite is true, with higher costs incurred as coverage is
increased. An organized HPV screening at 40% coverage would
require in excess of E1.1 M in programmatic costs. These findings
suggest that the costs of implementing primary HPV screening as
part of an organized programme of 5-yearly interventions would be
probably repaid within a few years and lead to annual savings of 22%
in subsequent years, including productivity losses.
Our study is the first in Europe to assess the total lifetime ex-
penditure of an opportunistic cytology screening vs. an organized
programme based on HPV screening within the same population.
The information already available in this regard for Spain was
limited to a cross-sectional study performed in the Autonomous
Region of Cantabria, which calculated the cost of opportunistic
cytology screening for the period 2006–2011.26 The direct costs
were reported as E567 567, which works out at E19.40 per
woman screened. This somewhat lower than our own calculations
suggest, but the authors do mention that the cost of primary care,
specialist visits, outpatient care and treatment were not included.
Figure 1 Estimated annual cost of current opportunistic cytology screening and organized HPV primary screening at different coverage
rates
Figure 2 Estimated annual cost per adult woman or screened woman aged 25–64 years of current opportunistic cytology screening and
organized HPV primary screening at different coverage rates
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Costs of productivity loss are reported at 40% of the total annual
expenditure. In 2014, the same group also calculated the cost of an
organized screening programme for different frequency and
coverage scenarios, though the primary screening method was
cytology, not HPV testing.27
Just one simulation model in Germany and two cost analyses in
Mexico and the United States have calculated cervical cancer cost
from the payer perspective (direct costs) in relation to screening
strategies based on primary HPV testing.28–30 In Germany
different HPV screening scenarios, all with 5-year screening
intervals, were compared to annual cytology screening with a time
horizon of 6 or 10 years. Direct costs were consistently lower with
HPV screening than with cytology. The annual cost for HPV
screening with cytology triage was E117 M, compared to E177 M
for cytology screening. This constitutes an annual saving of E60 M
(33.9%). When the compliance rate for HPV screening was set at a
constant 80%, cytology screening achieved comparable outcomes
when compliance rates were raised to just 64% in some scenarios.
In practice, very few countries recommend a screening interval of
1 year, with the majority recommending intervals of 3 to 5 years.
Considering a time horizon of 3 or 5 years, the authors in Mexico
also conclude that primary HPV screening costs less in all scenarios
than conventional cytology. The direct cost stood at US$98.9 M for
conventional cytology and US$97.9 M for HPV testing with cytology
triage, assuming a total of 5.6 M women screened (32% of women
aged 35–64). In the US, researchers used a 1-year time horizon
model, giving an annual direct cost per screened woman aged
30–65 of $41 for cytology at 3-year intervals. For primary HPV
screening with HPV16/18 genotyping, the cost is $30 at 5-year
intervals and $48 at 3-year intervals. These latter results broadly
match the costs obtained in our study per screened woman.
Annual expenditure on cytology screening protocols has been
estimated in Europe for Belgium, Finland, France, Germany, Italy,
Sweden and the UK, as well as on other continents.6,30–38 Direct
costs per woman vary widely. The variations may be attributable
to factors such as the differences in healthcare systems, screening
methods (conventional/liquid-based cytology), model outcomes
(cervical cancer, other HPV-related diseases) and/or consideration
of primary costs. For instance, the study in Finland did not include
the cost of treatment.
The recent European financial crisis has spawned economic
pressures on national health systems. In Spain the budget allocated
to health and social services has been reduced by around 15% over
the last few years, with additional budget cuts in some regions.39 The
impact of these measures are yet to be established, though it will
likely have adverse effects on determinants of health and health
inequalities.40 Responses to mitigate this impact should include al-
ternative policy interventions with a focus on population health and
based on scientific evidence.39
Our model does not include HPV triage for the cytology screening
scenario, which would likely result in lower costs and, therefore,
make the case for primary HPV screening less convincing. That
said, the model does not include cost estimates for the prevention
and treatment of HPV-related diseases other than cervical cancer
either. This factor would help to quantify the real economic
burden of HPV and the benefits of HPV vaccination, results
which would turn the tables back in favour of the implementation
of an organized programme based on HPV testing given vaccinated
populations. Mathematical models are based on a large number of
assumptions, some of which are more accurate than others.
Although existing analyses all point to the same or similar conclu-
sions, model uncertainty may be affecting the outcomes, so results
should be considered an approximation. Consequently, further
analyses are needed to confirm the findings and existing models
have to be renewed regularly as scientific knowledge progresses.
The findings of this study provide valuable information for health
decision makers in Catalonia that was not previously available.
European countries with a similar screening status and health infra-
structures may also find themselves reflected in this study and
consider the change to an organized screening with primary HPV
testing. We recommend that the new Catalan protocol on cervical
cancer incorporate HPV testing as the primary screening method. It
should also include guidelines to enable its implementation as part
of an organized programme without overloading the system and
drawing excessively on the health budget.
Supplementary data
Supplementary data are available at EURPUB online.
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Key points
 The same economic resources used under the current system
for opportunistic cytology screening at 40% coverage could
be used more efficiently to cover 70% of the population by
switching to primary HPV testing at 5-year intervals as part
of an organized screening programme.
 If vaccination against HPV of pre-teen girls is assumed,
primary HPV screening is even further justified, leading to
fewer infections and increasing the sensitivity of the HPV
test.
 European countries with comparable policies of opportun-
istic cytology screening and adequate health infrastructures
may find their own cases reflected in this assessment and be
persuaded of the benefits of switching to a policy of
organized screening by primary HPV testing.
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